CO2017007121A2 - Compuestos bicíclicos fusionados para el tratamiento de enfermedades - Google Patents

Compuestos bicíclicos fusionados para el tratamiento de enfermedades

Info

Publication number
CO2017007121A2
CO2017007121A2 CONC2017/0007121A CO2017007121A CO2017007121A2 CO 2017007121 A2 CO2017007121 A2 CO 2017007121A2 CO 2017007121 A CO2017007121 A CO 2017007121A CO 2017007121 A2 CO2017007121 A2 CO 2017007121A2
Authority
CO
Colombia
Prior art keywords
diseases
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
CONC2017/0007121A
Other languages
English (en)
Inventor
Raju Mohan
Benjamin Anthony Pratt
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55300724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017007121(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of CO2017007121A2 publication Critical patent/CO2017007121A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

En la presente, se describen compuestos bicíclicos fusionados, composiciones y métodos para su uso para el tratamiento de enfermedades.
CONC2017/0007121A 2014-12-22 2017-07-17 Compuestos bicíclicos fusionados para el tratamiento de enfermedades CO2017007121A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095646P 2014-12-22 2014-12-22
PCT/IB2015/002549 WO2016103037A1 (en) 2014-12-22 2015-12-21 Fused bicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
CO2017007121A2 true CO2017007121A2 (es) 2017-10-31

Family

ID=55300724

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0007121A CO2017007121A2 (es) 2014-12-22 2017-07-17 Compuestos bicíclicos fusionados para el tratamiento de enfermedades

Country Status (16)

Country Link
US (4) US10167294B2 (es)
EP (1) EP3237419B1 (es)
JP (2) JP2017538773A (es)
KR (1) KR20170117030A (es)
CN (1) CN107438612A (es)
AU (2) AU2015370588B2 (es)
BR (1) BR112017013568A2 (es)
CA (1) CA2971755A1 (es)
CL (1) CL2017001661A1 (es)
CO (1) CO2017007121A2 (es)
HK (1) HK1245795A1 (es)
IL (1) IL252849B (es)
MX (1) MX369623B (es)
RU (2) RU2021100040A (es)
SG (1) SG11201704770YA (es)
WO (1) WO2016103037A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015370588B2 (en) * 2014-12-22 2020-07-16 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CA2980394A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
TW201808283A (zh) * 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
TW202114671A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 包含fxr促效劑之治療
TW202114672A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 使用fxr促效劑的肝臟疾病之組合治療
WO2021044287A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
EP4031137A1 (en) 2019-09-19 2022-07-27 Novartis AG Treatment comprising fxr agonists
US20220331341A1 (en) 2019-09-30 2022-10-20 Novartis Ag Treatment comprising the use of fxr agonists
AU2020408067B2 (en) 2019-12-20 2024-03-28 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
JP2024500841A (ja) 2020-12-22 2024-01-10 ノバルティス アーゲー ｃＧＡＳと関連する病態の処置に有用なピロロ［３．２－ｂ］ピリジン誘導体
UY39579A (es) 2020-12-22 2022-07-29 Novartis Ag COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412262A (pt) * 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2015370588B2 (en) * 2014-12-22 2020-07-16 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
KR20170117030A (ko) 2017-10-20
CA2971755A1 (en) 2016-06-30
MX369623B (es) 2019-11-14
RU2741387C2 (ru) 2021-01-25
EP3237419B1 (en) 2021-02-17
SG11201704770YA (en) 2017-07-28
US20210139490A1 (en) 2021-05-13
US20170355704A1 (en) 2017-12-14
CL2017001661A1 (es) 2018-03-23
RU2017126128A3 (es) 2019-06-13
AU2020256336A1 (en) 2020-11-12
EP3237419A1 (en) 2017-11-01
BR112017013568A2 (pt) 2018-03-06
US10793577B2 (en) 2020-10-06
AU2015370588A1 (en) 2017-07-20
IL252849B (en) 2021-07-29
US10167294B2 (en) 2019-01-01
AU2015370588B2 (en) 2020-07-16
US20240025914A1 (en) 2024-01-25
IL252849A0 (en) 2017-08-31
US20190211026A1 (en) 2019-07-11
JP2021006564A (ja) 2021-01-21
RU2017126128A (ru) 2019-01-29
JP7089566B2 (ja) 2022-06-22
JP2017538773A (ja) 2017-12-28
CN107438612A (zh) 2017-12-05
MX2017008456A (es) 2018-03-01
HK1245795A1 (zh) 2018-08-31
RU2021100040A3 (es) 2021-04-26
RU2021100040A (ru) 2021-02-02
WO2016103037A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
SV2018005610A (es) Derivados de oxopiridina sustituidos
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2017000806A1 (es) Compuestos anti-tnf
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201790273A1 (ru) Флагеллиновые композиции и их применение
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ES2968042T3 (es) Uso de DREADD para la modulación neuronal en el tratamiento de enfermedades neuronales
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose